Solid Biosciences (SLDB)
NASDAQ:SLDB
SLDB Stock Chart & Stats
$6.68
$0.18(4.59%)
At close: 4:00 PM EST
$6.68
$0.18(4.59%)
Day’s Range― - ―
52-Week Range$2.41 - $8.72
Previous CloseN/A
Volume1.97M
Average Volume (3M)1.56M
Market Cap
$657.25M
Enterprise Value$523.33M
Total Cash (Recent Filing)$189.07M
Total Debt (Recent Filing)$21.16M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
May 07, 2026EPS Estimate
-0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding98,391,310
10 Day Avg. Volume1,872,422
30 Day Avg. Volume1,558,504
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.13
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-415.34
Enterprise Value/Ebitda-3.04
Forecast
1Y Price Target
$17.75Price Target Upside165.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacySGT-003 produces robust and consistent micro-dystrophin expression across an expanded patient group, with biopsy and biomarker signals of muscle preservation and improved cardiac measures that support a potential disease-modifying effect.
Regulatory PathwayPlanned engagement with the regulator and maturation of the INSPIRE dataset aim to clarify confirmatory trial expectations and could enable pursuit of an accelerated approval pathway if trial design and endpoints align.
Safety And TolerabilitySGT-003 has been delivered using a lower-burden, steroid-only outpatient immunomodulation approach and shows a favorable safety profile with rare, resolved serious events, which could improve physician and patient acceptance.
Bears Say
Financing RiskThe company reported no product revenue and continues to record operating losses, implying a need for additional external financing that could dilute shareholders or constrain development timelines.
Reputational And Scrutiny RiskDisclosed business relationships and expected investment banking compensation create potential conflicts of interest, while safety issues with a competing gene therapy increase scrutiny around immunosuppression and may heighten caution among families and clinicians.
Response VariabilityA subset of earlier patients experienced suboptimal micro-dystrophin expression, indicating individual variability that could complicate predictability of benefit and affect regulatory or commercial uptake.
Solid Biosciences News
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $2.41 and its highest was $8.72 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $657.25M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is May 07, 2026 which is in 42 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Mar 19, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.519 by -$0.011.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.44.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 98,391,310 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.519. Following the earnings report the stock price went down -1.264%.
Which hedge fund is a major shareholder of Solid Biosciences?
Currently, no hedge funds are holding shares in SLDB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Solid Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.75 (165.72% Upside)
$17.75 (165.72% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 211.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $809.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.74%
12-Months-Change
Fundamentals
Return on Equity
-73.34%
Trailing 12-Months
Asset Growth
23.26%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
SLDB Stock 12 Month Forecast
Average Price Target
$17.75
▲(165.72% Upside)